The Global NASH Council in the News

Metabolic dysfunction-associated steatotic liver disease (MASLD) now affects more than one-third of the global adult population and has become an increasingly important driver of cirrhosis, hepatocellular carcinoma, liver transplantation, and liver-related mortality. The newly accepted global consensus recommendations in Clinical Gastroenterology and Hepatology (2026) provide a practical roadmap to help clinicians move from passive disease...Continue reading→

A new study shows that we have been underestimating alcohol related liver disease. Published this week in The Lancet Gastroenterology and Hepatology by members of the Global NASH MASH Council, this large US study using NHANES data from 1988 to 2023 and including 41,100 adults highlights a major issue. Underreporting alcohol use is leading to...Continue reading→

The 6th Annual Liver Connect Meeting of the Chronic Liver Disease Foundation was held from February 26–28, 2026, at the Gaylord Pacific Resort & Convention Center in beautiful San Diego, California. The meeting brought together more than 500 in-person attendees, along with a substantial number of virtual participants from across the country and internationally. The...Continue reading→

The G-MASLD project with 18,759 biopsy-confirmed MASLD patients from 41 countries has been carried out by members of GNC. The project continues to provide critical data about MASLD/MASH and NITs from real world practices. In this analysis of G-MASLD data, the diagnostic accuracy and performance of NITs were influenced by patient characteristics. FIB-4 performance declined...Continue reading→

The Global NASH/MASH Council (GNC) was pleased to collaborate with Qatar Health Congress 2026 to address key topics in MASLD and MASH. The Congress was co-organized under the leadership of Professor Abdel-Naser Elzouki, Chair of the Scientific Committee and a member of the GNC, by the Department of Medicine at Hamad Medical Corporation, in collaboration...Continue reading→

The first Paris International Liver Meeting (PILM 2026) was a highly successful three-day scientific conference held from January 19–21, 2026. The meeting featured outstanding scientific sessions covering key areas including MASLD, MetALD, alcohol-associated liver disease, viral hepatitis, hepatocellular carcinoma, cholestatic liver diseases, and complications of cirrhosis. To watch the highlights from the meeting, please click...Continue reading→

The first Paris International Liver Meeting (PILM 2026) was organized by Professors Laurent Castera and Zobair Younossi, together with the Scientific Committee. This three-day meeting was attended by 722 participants (449 on site and 273 virtual) from 67 countries and was highly successful. Scientific sessions covered key areas including MASLD, MetALD, alcohol-associated liver disease, hepatocellular...Continue reading→

We’re excited to take part in the inaugural Paris International Liver Meeting (PILM), held 19–21 January 2026 at the historic Maison de la Chimie in Paris. PILM 2026 will showcase a robust program featuring global leaders in Steatotic Liver Disease (MASLD/MASH, MetALD, ALD), cholestatic liver disease (PBC, PSC), viral hepatitis, and complications of cirrhosis. Each...Continue reading→

Members of the Global NASH/MASH Council (GNC) have recently published two major original manuscripts in Hepatology. The GNC Collaborators created the Global-MASLD project, a cohort of 17,792 biopsy-proven MASLD cases with extensive clinical, laboratory, non-invasive test (NIT) data, and long-term outcomes. In the first manuscript, “Global Performance of Non-Invasive Tests in MASLD: Insights from the...Continue reading→